The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the exception to that rule is very informative you remember two of those drugs kagin and 17 Alpha estradiol extend lifespan in males only and ucp1 goes up in males only for those two drugs which is a a strong indication that whatever process is making the drugs slow the uh uh mortality rate and increased longevity is the same process at least in its sex specificity as the ucp1 story
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.